ReviewCancers2025

BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL.

Ross T Salvaris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.